On December 5, 2024, the Board discussed the DEA/HHS extension of COVID-19 telemedicine flexibilities for prescribing controlled substances through December 31, 2025.  The Board agreed to accept the federal position at this time.  

 

Resources: 

https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025

https://www.federalregister.gov/documents/2024/11/19/2024-27018/third-temporary-extension-of-covid-19-telemedicine-flexibilities-for-prescription-of-controlled